Biotech Values

[DewDiligence]

Thanks for the additional color. I’m not sure I understand how the Folgers case applies to ABT. Is it correct to say that ABT’s spun-off pharma company could immediately be acquired on a tax-free basis to ABT provided that the transaction has not been agreed to in advance of the spinoff? Or are you saying that ABT’s spun-off company could be acquired on a tax-free basis to ABT regardless of any agreements prior to the spin? T.i.a.